HCA Gives $1 Million in Aid for Ebola Response
Health Information

Vitamin B3

  • Home
  • Health Information

Supplement Forms/Alternate Names:

  • Niacin
  • Niacinamide
  • Nicotinamide
  • Inositol Hexaniacinate

Uses

Probably Not Effective Uses

  • Diabetes (Prevention in Children at High Risk)
  • Passing a Urine Drug Screen (Dangerous as well as Ineffective)

Vitamin B 3 is required for the proper function of more than 50 enzymes. Without it, your body would not be able to release energy or make fats from carbohydrates. Vitamin B 3 is also used to make sex hormones and other important chemical signal molecules.

Vitamin B 3 comes in two principal forms: niacin (nicotinic acid) and niacinamide (nicotinamide). When taken in low doses for nutritional purposes, these two forms of the vitamin are essentially identical. However, each has its own particular effects when taken in high doses. Additionally, a special form of niacin called inositol hexaniacinate has shown some promise as a treatment with special properties of its own.

Requirements/Sources

The official US and Canadian recommendations for daily intake of niacin are as follows:

  • Infants
    • 0-6 months: 2 mg
    • 7-12 months: 4 mg
  • Children
    • 1-3 years: 6 mg
    • 4-8 years: 8 mg
    • 9-13 years: 12 mg
  • Males
    • 14 years and older: 16 mg
  • Females
    • 14 years and older: 14 mg
  • Pregnant Women : 18 mg
  • Nursing Women : 17 mg

Because the body can make niacin from the common amino acid tryptophan, niacin deficiencies are rare in developed countries. However, the antituberculosis drug isoniazid (INH) impairs the body's ability to produce niacin from tryptophan and may create symptoms of niacin deficiency. 1,2

Good food sources of niacin are seeds, yeast, bran, peanuts (especially with skins), wild rice, brown rice, whole wheat, barley, almonds, and peas. Tryptophan is found in protein foods (meat, poultry, dairy products, fish). Turkey and milk are particularly excellent sources of tryptophan.

Therapeutic Dosages

When used as therapy for a specific disease, niacin, niacinamide, and inositol hexaniacinate are taken in dosages much higher than nutritional needs, about 1 to 4 g daily. Because of the risk of liver inflammation at these doses, medical supervision is essential.

Many people experience an unpleasant flushing sensation and headache when they take niacin. These symptoms can usually be reduced by gradually increasing the dosage over several weeks or by using slow-release niacin. However, slow-release niacin appears to be more likely to cause liver inflammation than other forms. Inositol hexaniacinate may also cause less flushing than plain niacin, and if you take an aspirin along with niacin, the flushing reaction will usually decrease.

Therapeutic Uses

There is no question that niacin (but not niacinamide) can significantly improve cholesterol profile, reducing levels of total and LDL ("bad") cholesterol and raising HDL ("good") cholesterol. 3-10 However, unpleasant flushing reactions as well as a risk of liver inflammation and dangerous interactions with other cholesterol-lowering drugs have kept niacin from being widely used (see Safety Issues ).

Niacinamide may improve blood sugar control in both children and adults who already have diabetes. 12,13 In addition, some evidence had suggested that regular use of niacinamide (but not niacin) might help preventdiabetes in children at special risk of developing it; 11 unfortunately, subsequent studies indicate that it probably does not work. 68,69

Preliminary evidence suggests that niacinamide may be able to decrease symptoms of osteoarthritis16 and help control polymorphous light eruption, a type of photosensitivity . 17

Somewhat surprisingly, topical niacinamide has shown some promise for skin conditions. In a double-blind study of 50 women with signs of aging skin , use of a niacinamide cream significantly improved skin appearance and elasticity as compared to placebo cream. 66 Niacinamide cream has also shown promise for rosacea . 67

The inositol hexaniacinate form of niacin (taken orally) may be helpful for intermittent claudication14 and Raynaud's phenomenon . 15  

In addition, weak and in some cases contradictory evidence suggests one of the several forms of niacin might be helpful for people with bursitis , 18cataracts , 19HIV infection, 20,21pregnancy , 22schizophrenia , 57-63 and tardive dyskinesia . 23

A new use of niacin was reported in 2007: it appears that some people take very high doses of niacin (in the neighborhood of 2.5 to 5 grams at a time ) in the belief that it will mask drugs in the urine. 70 However, not only does niacin fail to conceal the presence of drugs on a urine drug screen, when taken suddenly at doses this high, niacin can cause life-threatening problems involving the liver and heart. In addition, it can dangerously disturb blood sugar regulation and blood coagulation.

What Is the Scientific Evidence for Vitamin B

Niacin is one of the best researched of all the vitamins, and the evidence for using it to treat at least one condition—high cholesterol—is strong enough that it has become an accepted mainstream treatment.

High Cholesterol/Triglycerides

Niacin has been used since the 1950s to improve cholesterol profile. Several well-designed double-blind, placebo-controlled studies have found that niacin can reduce LDL ("bad") cholesterol by approximately 10% and triglycerides by 25% while raising HDL ("good") cholesterol by 20% to 30%. 24-29 Niacin also lowers levels of lipoprotein(a)—another risk factor for atherosclerosis—by about 35%. Long-term studies have shown that use of niacin can significantly reduce death rates from cardiovascular disease. 30

Niacin appears to be a safe and effective treatment for high cholesterol in people with diabetes as well, and (contrary to previous reports) does not seem to raise blood sugar levels. 31

Treating Diabetes

When a child develops diabetes, there is an interval called the honeymoon period in which the pancreas can still make some insulin and there is little to no need for injected insulin. Weak evidence suggests that niacinamide might slightly delay the onset of more severe symptoms. 34 A cocktail of niacinamide plus antioxidant vitamins and minerals has also been tried, but the results were disappointing in one study. 35 However, in another study, use of intensive insulin therapy along with niacinamide and vitamin E was more effective than insulin plus niacinamide alone in prolonging the honeymoon period. 64

A recent study suggests that niacinamide may also improve blood sugar control in type 2 (adult-onset) diabetes, but it did not use a double-blind design. 36 (For information on why this is important, see Why Does This Database Rely on Double-blind Studies? )

Intermittent Claudication

Double-blind studies involving a total of about 400 individuals have found that inositol hexaniacinate can improve walking distance for people with intermittent claudication . 37-40 For example, in one study, 100 individuals were given either placebo or 4 g of inositol hexaniacinate daily. 41 Over a period of 3 months, participants improved significantly in the number of steps they could take on a special device before experiencing excessive pain.

Osteoarthritis

There is some evidence that niacinamide may provide some benefits for those with osteoarthritis . In a double-blind study, 72 people with arthritis were given either 3,000 mg daily of niacinamide (in 6 equal doses) or placebo for 12 weeks. 42 The results showed that treated participants experienced a 29% improvement in symptoms, whereas those given placebo worsened by 10%. However, at this dose, liver inflammation is a concern that must be taken seriously.

Raynaud's Phenomenon

According to one small double-blind study, the inositol hexaniacinate form of niacin may be helpful for Raynaud's phenomenon . 43 The dosage used was 4 g daily—once again a dosage high enough for liver inflammation to be a real possibility.

Safety Issues

When taken at a dosage of more than 100 mg daily, niacin frequently causes annoying skin flushing, especially in the face, as well as stomach distress, itching, and headache. 65 In studies, as many as 43% of individuals taking niacin quit because of unpleasant side effects. 44

A more dangerous effect of niacin is liver inflammation. Although some reports suggest that it occurs most commonly with slow-release niacin, it can occur with any type of niacin when taken at a daily dose of more than 500 mg (usually 3 g or more). Regular blood tests to evaluate liver function are, therefore, mandatory when using high-dose niacin (or niacinamide or inositol hexaniacinate). This reaction almost always goes away when niacin is stopped. Note : Contrary to claims on some manufacturer's websites, there is no reliable evidence that inositol hexaniacinate is safer than ordinary niacin.

As noted above, a single dose of 2.5 to 5 grams of niacin (used in the vain hope of passing a urine drug test despite the presence of drugs in the system) can cause life-threatening disturbances in body function. 70 Since this range includes the high-end of the dosage used for treating cholesterol, presumably people who gradually work up to taking several grams of niacin daily can accommodate it in a way that those who take it suddenly cannot.

If you have liver disease, ulcers (presently or in the past), gout, or drink too much alcohol, 45 do not take high-dose niacin except on medical advice.

While there has been some concern that niacin may raise blood sugar levels in diabetics, the effect appears to be slight, and it carries little, if any, clinical significance. 46,56,71

Combining high-dose niacin with statin drugs (the most effective medications for high cholesterol) further improves cholesterol profile by raising HDL (“good”) cholesterol. 52-54 Unfortunately, there are real concerns that this combination therapy could cause a potentially fatal condition called rhabdomyolysis.

A growing body of evidence, however, suggests that the risk is relatively slight in individuals with healthy kidneys. Furthermore, even much lower doses of niacin than the usual dose given to improve cholesterol levels (100 mg versus 1,000 mg or more) may provide a similar benefit. 55 At this dose, the risk of rhabdomyolysis should be decreased.

Nonetheless, it is not safe to try this combination except under close physician supervision. Rhabdomyolysis can be fatal.

Another potential drug interaction involves the anticonvulsant drugs carbamazepine and primidone . Niacinamide might increase blood levels of these drugs, possibly requiring reduction in drug dosage. 50 Do not use this combination except under physician supervision.

The maximum safe dosage of niacin for pregnant or nursing women has been set at 35 mg daily (30 mg if 18 years old or younger). 51

Interactions You Should Know About

If you are taking:

  • Cholesterol-lowering drugs in the statin family, niacin might offer potential benefits; however, there are real dangers to this combination. Do not try it except under physician supervision.
  • The antituberculosis drug isoniazid (INH) : You may need extra niacin.
  • Anticonvulsant drugs such as carbamazepine or primidone : Do not take niacinamide except under physician supervision.

If you drink alcohol excessively:

  • Do not take niacin except under physician supervision.

Revision Information

  • 1

    DiLorenzo PA. Pellagra-like syndrome associated with isoniazid therapy. Acta Derm Venereol . 1967;47:318-322.

  • 2

    Ishii N, Nishihara Y. Pellagra encephalopathy among tuberculous patients: its relation to isoniazid therapy. J Neurol Neurosurg Psychiatry. 1985;48:628-634.

  • 3

    Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med . 1994;154:1586-1595.

  • 4

    Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol . 1998;82:737-743.

  • 5

    Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med . 1994;154:73-82.

  • 6

    Lal SM, Hewett JE, Petroski G, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis . 1995;25:616-622.

  • 7

    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol . 1986;8:1245-1255.

  • 8

    Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Arch Intern Med. 2000;160:1177-1184.

  • 9

    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA. 2000;284:1263-1270.

  • 10

    Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: A placebo-controlled trial. J Cardiovasc Pharmacol Ther . 1996;1:195-202.

  • 11

    Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab . 1996;9:501-509.

  • 12

    Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia . 1995;38:848-852.

  • 13

    Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol . 1998;35:61-64.

  • 14

    Head KA. Inositol hexaniacinate: a safer alternative to niacin. Altern Med Rev . 1996;1:176-184.

  • 15

    Sunderland GT, Belch JJ, Sturrock RD, et al. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol . 1988;7:46-49.

  • 16

    Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996;45:330-334.

  • 17

    Neumann R, Rappold E, Pohl-Markl H. Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br J Dermatol. 1986;115:77-80.

  • 18

    Kellman M. Bursitis: a new chemotherapeutic approach. J Am Osteopathic Assoc . 1962;61:896-903.

  • 19

    Sperduto RD, Hu TS, Milton RC, et al. The Linxian cataract studies. Two nutrition intervention trials. Arch Ophthamol . 1993;111:1246-1253.

  • 20

    Tang AM, Graham NM, Saah AJ. Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. Am J Epidemiol. 1996;143:1244-1256.

  • 21

    Tang AM, Graham NHM, Kirby AJ, et al. Dietary micronutrient intake and risk of progression to acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus type 1 (HIV-1)-infected homosexual men. Am J Epidemiol. 1993;138:937-951.

  • 22

    Doyle W, Crawford MA, Wynn AH, et al. The association between maternal diet and birth dimensions. J Nutr Med . 1990;1:9-17.

  • 23

    Kunin RA. Manganese and niacin in the treatment of drug-induced tardive dyskinesias. J Orthomol Psychiatry 5:4-27, 1976. In: Werbach MR. Nutritional Influences on Illness [book on CD-ROM]. 2nd ed. Tarzana, CA; 1996.

  • 24

    Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med . 1994;154:1586-1595.

  • 25

    Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol . 1998;82:737-743.

  • 26

    Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med . 1994;154:73-82.

  • 27

    Lal SM, Hewett JE, Petroski G, et al. Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial. Am J Kidney Dis . 1995;25:616-622.

  • 28

    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA . 2000;284:1263-1270.

  • 29

    Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled trial. J Cardiovasc Pharmacol Ther . 1996;1:195-202.

  • 30

    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol . 1986;8:1245-1255.

  • 31

    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA. 2000;284:1263-1270.

  • 32

    Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab. 1996;9:501-509.

  • 33

    Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes . 1998;47:980-984.

  • 34

    Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia . 1995;38:848-852.

  • 35

    Ludvigsson J, Samuelsson U, Johansson C, et al. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. Diabetes Metab Res Rev . 2001;17:131-136.

  • 36

    Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol . 1998;35:61-64.

  • 37

    O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract . 1988;42:377-383.

  • 38

    Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. Br J Clin Pract . 1988;42:141-145.

  • 39

    Head A. Treatment of intermittent claudication with inositol nicotinate. Practitioner . 1986;230:49-54.

  • 40

    Tyson VC. Treatment of intermittent claudication. Practitioner . 1979;223:121-126.

  • 41

    O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract . 1988;42:377-383.

  • 42

    Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996;45:330-334.

  • 43

    Sunderland GT, Belch JJ, Sturrock RD, et al. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. Clin Rheumatol . 1988;7:46-49.

  • 44

    Gibbons LW, Gonzalez V, Gordon N, at al. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med . 1995;99:378-385.

  • 45

    Physicians' Desk Reference. Montvale, NJ: Medical Economics Co; 1999:1507.

  • 46

    Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients With diabetes and peripheral arterial disease. The ADMIT Study: a randomized trial. JAMA . 2000;284:1263-1270.

  • 47

    Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol. 1994;73:25D-29D.

  • 48

    Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. J Am Coll Cardiol. 2000;35(suppl A):326.

  • 49

    Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol . 2001;87:476-479.

  • 50

    Bourgeois BFD, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide. Neurology. 1982;32:1122-1126.

  • 51

    Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B 6 , Folate, Vitamin B 12 , Pantothenic Acid, Biotin, and Choline (1998). The National Academies Press website. Available at http://www.nap.edu . Accessed October 4, 2001.

  • 52

    Jacobson TA, Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: a preliminary report on safety. Am J Cardiol. 1994;73:25D-29D.

  • 53

    Kashyap ML, Evans R, Simmons PD, et al. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated. J Am Coll Cardiol. 2000;35(suppl A):326.

  • 54

    Wolfe ML, Vartanian SF, Ross JL, et al. Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol. 2001;87:476-479.

  • 55

    Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. Am Heart J. 2002;143:514-518.

  • 56

    Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med . 2002;162:1568-1576.

  • 57

    Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. Can Psychiatr Assoc J . 1973;18:377-383.

  • 58

    Hawkins DR, Bortin AW, Runyon RP. Orthomolecular psychiatry: niacin and megavitamin therapy. Psychosomatics. 1970;11:517-521.

  • 59

    Hoffer A. Megavitamin B-3 therapy for schizophrenia. Can Psychiatr Assoc J. 1971;16:499-504.

  • 60

    Newbold HL, Mosher LR. Niacin and the schizophrenic patient. Am J Psychiatry. 1970;127:535-536.

  • 61

    Petrie WM, Ban TA. Vitamins in psychiatry. Do they have a role? Drugs. 1985;30:58-65.

  • 62

    Procter A. Enhancement of recovery from psychiatric illness by methylfolate. Br J Psychiatry . 1991;159:271-272.

  • 63

    Wittenborn JR, Weber ES, Brown M. Niacin in the long-term treatment of schizophrenia. Arch Gen Psychiatry . 1973;28:308-315.

  • 64

    Crino A, Schiaffini R, Manfrini S, et al. A randomized trial of nicotinamide and vitamin E in children with recent onset type 1 diabetes (IMDIAB IX). Eur J Endocrinol . 2004;150:719-724.

  • 65

    Mills EJ, Prousky J, Raskin G, et al. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol . 2003 Nov 13. [Epub ahead of print]

  • 66

    Bissett DL, Oblong JE, Berge CA, et al. Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol Surg . 2005;31:860-865; discussion 865.

  • 67

    Draelos ZD, Ertel K, Berge C, et al. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis . 2005;76:135-141.

  • 68

    Gale EA, Bingley PJ, Emmett CL, et al. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet . 2004;363:925-931.

  • 69

    Cabrera-Rode E, Molina G, Arranz C, et al. Effect of standard nicotinamide in the prevention of type 1 diabetes in first degree relatives of persons with type 1 diabetes. Autoimmunity. 2006;39:333-340

  • 70

    Mittal MK, Florin T, Perrone J, et al. Toxicity from the use of niacin to beat urine drug screening. Ann Emerg Med . Epub 2007 Apr 6.

  • 71

    Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc. 2008;83:470-478.